Advertisement

Picture EBD Group Asia Bio Partnering Forum 2025 Singapore 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2731 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Azafaros–Schroders: investment, 202505 financing round Series B totalling €132m incl existing + co-investor Schroders Capital 2025-05-13
Azafaros–Seroba: investment, 202505 financing round Series B totalling €132m incl new + co-investor Seroba 2025-05-13
Azafaros–SEVERAL: investment, 202505 financing round Series B €132m led by Jeito Capital + co-led by Forbion Growth 2025-05-13
Haya Therapeutics–Schroders: investment, 202505 financing round Series A totalling $65m incl existing + co-investor Schroders Capital 2025-05-08
Haya Therapeutics–SEVERAL: investment, 202505 financing round Series A $65m led by Sofinnova Partners + Earlybird VC 2025-05-08
Boehringer–Tessellate Bio: cancer drugs, 202504– collab research + license ww up to >€500m precision treatments for hard-to-treat cancers 2025-04-23
Biotage–KKR: investment, 202504– public takeover offer by RWK BidCo AB valuing Biotage at SEK11.6b at SEK1.65/share (KKR already owns 17%) 2025-04-22
Alis Biosciences–Optimum Strategic Communications: public relations, 202504 service existent by Optimum 2025-04-18
Glycomine–SEVERAL: investment, 202504 financing round Series C $115m led by CTI Life Sciences Fund + abrdn Inc + Advent Life Sciences 2025-04-16
Astellas–Chromatin Bioscience: synthetic promoters, 202504– collab using chromatinLENS platform to design promoters aligned w Astellas’ target profile 2025-04-14
1st PhileKorea–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in South Korea by 1st PhileKorea 2025-04-09
As One Corp–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in Japan by 1st PhileKorea 2025-04-09
Bang Trading–Sphere Bio: cell analysis technology, 202504 distribution existent for Sphere Bio in Thailand by Bang Trading 2025-04-09
Cold Spring Biotech–Sphere Bio: cell analysis technology, 202504 distribution existent for Sphere Bio in Taiwan by Cold Spring Biotech 2025-04-09
Decode Science–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in Australia + New Zealand by Decode Science 2025-04-09
Everlife Research Instruments–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in Singapore by Everlife 2025-04-09
Gene Company–Sphere Bio: cell analysis technology, 202504 distribution existent for Sphere Bio in China + Hong Kong by Gene Company 2025-04-09
Immunic–Aberdeen Group: investment, 202504 registered directed offering totalling $5.1m incl lead investor Aberdeen Investments 2025-04-09
Immunic–SEVERAL: investment, 202504 registered directed offering $5.1m led by Aberdeen Investments with 5.67m shares common stock at $0.9/share 2025-04-09
Premas Life Sciences–Sphere Bio: cell analysis technology, 202504– distribution for Sphere Bio in India + Bangladesh by Premas Life Sciences 2025-04-09
Dotmatics–Siemens: investment, 202402– acquisition $5.1b of Dotmatics from Insight Partners ANNOUNCED 2025-04-02
Nuage Therapeutics–Vigo Consulting: public relations, 202504 service existent by Vigo Consulting 2025-04-01
Isomorphic Labs–Alphabet: investment, 202503 first external financing round totalling $600m incl co-investor GV 2025-03-31
Isomorphic Labs–Alphabet: investment, 202503 first external financing round totalling $600m incl existing + co-investor Alphabet 2025-03-31
Isomorphic Labs–SEVERAL: investment, 202503 first external financing round $600m led by Thrive Capital 2025-03-31
Isomorphic Labs–Thrive Capital: investment, 202503 first external financing round totalling $600m incl lead investor Thrive Capital 2025-03-31
Amboss–Lightrock: investment, 202503 financing round totalling €240m incl new + co-lead investorLightrock 2025-03-25
Amboss–M&G: investment, 202503 financing round totalling €240m incl new + co-lead investor M&G Investments 2025-03-25
Amboss–OTHER: investment, 202503 financing round totalling €240m incl existing investors as co-investors 2025-03-25
Amboss–SEVERAL: investment, 202503 financing round €240m led by Kirkbi + M&G Investments + Lightrock 2025-03-25
AstraZeneca–Beijing (govt): business park, 202503– strategic partnership involving $2.5b investment by AstraZeneca in Beijing BioPark + collaborations 2025-03-21
AstraZeneca–Beijing Cancer Hospital: cancer drugs, 202503– strategic partnership in translational research + data science + clinical development 2025-03-21
AstraZeneca–BioKangtai: vaccines, 202503– collab joint venture in Beijing to develop + manufacture + commercialise vaccines 2025-03-21
AstraZeneca–Harbour BioMed: therapeutic antibodies, 202503– collab + license agreem to discover multi-specific antibodies 2025-03-21
AstraZeneca–Syneron Bio: peptide therapeutics, 202503– collab + license agreem to develop macrocyclic peptides 2025-03-21
Thena Capital–SEVERAL: investment, 202503 first close £27m of in augural UK MedTech Fund with cornerstone commitment from British Business Bank 2025-03-21
Roche–Oxford BioTherapeutics: antibody cancer drugs, 202503– collab strategic $36m upfront + >$1b milestones using OGAP Verify for Ab cancer drugs 2025-03-19
Forth Therapeutics–SEVERAL: investment, 202503 launch with seed investment round from Sofinnova Partners + Old College Capital 2025-03-18
Forth Therapeutics–Sofinnova: investment, 202503 launch with seed investment round incl founding investor Sofinnova Biovelocita II fund 2025-03-18
Forth Therapeutics–Univ Edinburgh: investment, 202503 launch with seed investment round incl founding investor Old College Capital 2025-03-18
AstraZeneca–Alteogen: drug delivery technology, 202503– license ww + supply to use ALT-B4 to develop + market sc formulations of cancer drugs 2025-03-17
EsoBiotec–AstraZeneca: investment, 202503 acquisition $425m upfront + $575m milestones on cash/debt free basis 2025-03-17
Chimerix–Jazz Pharmaceuticals: investment, 202503– acquisition cash tender offer $935m at $8.55/share by Jazz Pharmaceuticals 2025-03-05
Epoch Biodesign–Extantia Capital: investment, 202503 financing round Series A totalling $17.3m incl lead investor Extantia Capital 2025-03-05
Epoch Biodesign–SEVERAL: investment, 202503 financing round Series A $17.3m led by Extantia Capital 2025-03-05
Epoch Biodesign–United Kingdom (govt): grant, 202503c grant $1m from UK govt 2025-03-05
Trimtech Therapeutics–SEVERAL: investment, 202503 seed financing round £25m led by Cambridge Innovationn Capital + DDF 2025-03-05
Xund Solutions–SEVERAL: investment, 202503 financing round pre-Series A €6m led by Lead Ventures 2025-03-05
FibroGen–AstraZeneca: investment, 202502 acquisition $160m (incl acquired net cash of $75m) of FibroGen China by AZ incl rights to roxadustat in China 2025-02-20
Anbio Biotechnology–SEVERAL: investment, 202502 IPO $8m net $7.44m at Nasdaq Global Market with 1.6m Class A ordinary shares at $5/share 2025-02-18
Novartis–Isomorphic Labs: AI-based drug discovery, 202502– collab expansion adding up to 3 research programs same financial terms as agreem in 1/24 2025-02-18
Latent Labs–SEVERAL: investment, 202502 financing round Series A $40m co-led by Radical Ventures + Sofinnova Partners 2025-02-13
Latent Labs–SEVERAL: investment, <202502 financing round pre-Series A? $10m incl 8VC + Kindred Capital + Pillar VC 2025-02-13
Ochre Bio–Som.X: public relations, 202502 service existent? Ochrebio listed as client at web site 2025-02-13
Ori Biotech–Som.X: public relations, 202502 service existent? Oribiotech listed as client at web site 2025-02-13
Pfizer–Som.X: public relations, 202502 service existent? Pfizer listed as client at web site 2025-02-13
Avalyn Pharma–Qureight: drug development services, 202502– collab using Qureight imaging technology in multiple Avalyn clinical studies 2025-02-05
Qureight–Som.X: public relations, 202502 service existent SomX is media contact for Qureight 2025-02-05
Akribion–Optimum Strategic Communications: public relations, 202502 service existent by Optimum 2025-02-04
Quibim–SEVERAL: investment, 202501 financing round Series A $50m led by Asabys + Beunavista Equity Partners 2025-01-28
4basebio–Circio: synthetic DNA vectors, 202501– collab developm integration of circVEC system with Hermes platform + hpDNA + opDNA 2025-01-21
JnJ–Chromatin Bioscience: synthetic promoter design, 202501– collab leveraging chromatinLENS platform 2025-01-20
Zwisler Laboratorium–Cormica: investment, 202501 acquisition of Zwisler Laboratorium GmbH by Cormica 2025-01-20
EsoBiotec–Chromatin Bioscience: synthetic promoters, –202501– collab existent using chromatinLENS platform to design promoters for EsoBiotec 2025-01-17
Owlstone–Aviva: investment, 202501 financing round Series E first closing totalling $27m incl existing + co-investor Aviva Ventures 2025-01-15
Owlstone–Gates Foundation: grant, 202404– initial $1.5m grant to develop breat-based diagnostics for developing countries from Gates Foundation 2025-01-15
Owlstone–Horizons Ventures: investment, 202501 financing round Series E first closing totalling $27m incl existing + co-investor Horizon Ventures 2025-01-15
Owlstone–SEVERAL: investment, 202501 financing round Series E first closing $27m led by Ventura Capital 2025-01-15
Owlstone–Ventura Capital: investment, 202501 financing round Series E first closing totalling $27m incl existing + lead investor Ventura Capital 2025-01-15
Bioptimus–SEVERAL: investment, 202501 financing round $41m led by Cathay Innovation 2025-01-14
IDRx–GSK: investment, 202501– acquisition 100% of IDRx for $1b upfront + $150m milestones by GSK 2025-01-13
Windward Bio–SEVERAL: investment, 202501 financing round Series A $200m led by OrbiMed + Novo Holdings + Blue Owl Healthcare Opportunities 2025-01-10
Windward Bio–SR One: investment, 202501 financing round Series A totalling $200m incl co-investor SR One 2025-01-10
Coave Therapeutics–Seroba: investment, 202501 financing round Series A totalling €32m incl existing + co-investor Seroba Life Sciences 2025-01-09
Coave Therapeutics–SEVERAL: investment, 202501 financing round Series A €32m co-led by Novo Holdings + Bpifrance InnoBio 2025-01-09
Pregene Biopharma–EsoBiotec: CAR T-cell therapy, 202501 collab existent development of ESO-T01 (in China?) 2025-01-08
Ottimo Pharma–Avoro Capital: investment, 202412 financing round Series A totalling >$140m incl co-lead investor Avoro Capital 2024-12-19
Ottimo Pharma–Decheng Capital: investment, 202412 financing round Series A totalling >$140m incl co-investor Decheng Capital 2024-12-19
Ottimo Pharma–Invus Group: investment, 202412 financing round Series A totalling >$140m incl co-investor Invus 2024-12-19
Ottimo Pharma–Janus Henderson: investment, 202412 financing round Series A totalling >$140m incl co-investor Janus Henderson Investors 2024-12-19
Ottimo Pharma–JPMorgan Chase: investment, 202412 financing round Series A totalling >$140m incl co-investor JP Morgan Life Sciences Private Capital 2024-12-19
Ottimo Pharma–Medicxi Ventures: investment, 202412 financing round Series A totalling >$140m incl existing + co-investor Medicxi 2024-12-19
Ottimo Pharma–OrbiMed: investment, 202412 financing round Series A totalling >$140m incl co-lead investor OrbiMed 2024-12-19
Ottimo Pharma–RTW Investments: investment, 202412 financing round Series A totalling >$140m incl co-investor RTW Investments 2024-12-19
Ottimo Pharma–Samsara BioCapital: investment, 202412 financing round Series A totalling >$140m incl co-lead investor Samsara BioCapital 2024-12-19
Ottimo Pharma–SEVERAL: investment, 202412 financing round Series A >$140m led by OrbiMed + Avoro Capital + Samsara BioCapital 2024-12-19
VectorY–Vigo Consulting: public relations, 202412 service existent by Vigo Consulting 2024-12-16
Andera Partners–New York Life: investment, 202412– acquisition €na of 40% minority share in Andera by New York Life Investments 2024-12-12
BenevolentAI–ICR: public relations, 202412 service existent by ICR Healthcare Europe 2024-12-11
Fresenius–Ori Biotech: CGT manufacturing technology, 202412– collab integration IRO platform with up + downstream processing tech of Fresenius Kabi 2024-12-10
GSK–Relation Therapeutics: drug target discovery, 202412– two collab $30m upfront + $263m milestones + royalties in fibrotic diseases + osteoarthritis 2024-12-10
Relation Therapeutics–GSK: investment, 202412 equity investment $15m in connection with strategic collaborations 2024-12-10
Citryll–ICR: public relations, 202412 service existent by ICR Healthcare Europe 2024-12-09
GSK–Muna Therapeutics: drug target discovery, 202412– collab strategic alliance €33.5m upfront + milestones MiND-MAP platform for Alzheimer targets 2024-12-05
Newcells Biotech–SEVERAL: investment, 202412 financing round £1.2m from existing investors Mercia Ventures + Northstar Ventures + North East Finance 2024-12-05
HexagonFab–Merck (DE): investment, 202412 financing round Series A totalling £6.6m of Abselion incl lead investor M Ventures 2024-12-04
HexagonFab–SEVERAL: investment, 202412 financing round Series A £6.6m of Abselion led by M Ventures 2024-12-04
Cradle Bio–Index Ventures: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Index Ventures 2024-11-26
Cradle Bio–Institutional Venture Partners: investment, 202411 financing round Series B totalling $73m incl new + lead investor IVP 2024-11-26
Cradle Bio–Kindred Capital: investment, 202411 financing round Series B totalling $73m incl existing + co-investor Kindred Capital 2024-11-26
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  next pagenext page



Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture biomindz TRON LSG Mainz Translation Cancer Immunotherapy 650x300px

» top